Company intelligence / Profile preview

Avexima

Moscow, Moscow, Russia

Ownership: Private
Employees: ~5000
Development stage: Other

Overview

Avexima is one of Russia's largest manufacturers of active pharmaceutical ingredients and finished medicines, with a diverse portfolio of commercial-stage drugs spanning gynecology, urology, cardiology, neurology, gastrointestinal and musculoskeletal diseases, and more. Currently expanding its capacity with new production clusters for further drug development and manufacturing, including oncology and biotechnology products.

Therapeutic areas: ImmunologyEndocrinologyRheumatologyMetabolic DisordersMen's HealthInfectious DiseasesGastroenterologyDermatologyCardiovascularOncologyNeurologyWomen's Health
Modalities: Small moleculeBiologicPeptidesVaccine
Industry: Biotech

Drug pipeline

1 asset

Benzonal

Unknown

Partnerships

FC Grand Capital

Beyond the preview

Go deeper on Avexima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avexima.

Explore the full profile